25 completed, 10 terminated, 7 active not recruiting, 6 recruiting. 33 Phase 2, 25 Phase 1, 2 Phase 3, 1 Early Phase 1, 1 Phase 4.
Follow Mek162: new trials by email Literature Review of Mek162 trials Research Report on Mek162
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial) Binimetinib, Biopsy Procedure, Biospecimen Collection - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 1 | 2024-09-13 | 2026-03-03 |
| Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) Binimetinib, Biopsy Procedure, Biospecimen Collection - Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 17 | 2024-02-09 | 2026-10-19 |
| Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer Binimetinib, Palbociclib, Therapeutic Conventional Surgery - Colorectal Carcinoma, Lung Adenocarcinoma | Early Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2024-01-15 | 2023-12-22 | |
| Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial Binimetinib, Biopsy Procedure, Biospecimen Collection - Exocrine Pancreas Carcinoma, Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 199 | 2023-12-13 | 2026-08-21 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial Alpelisib, Binimetinib, Biopsy Procedure - Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2900 | 2023-04-07 | 2026-10-15 |
| Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer BET Bromodomain Inhibitor ZEN-3694, Binimetinib, Biopsy Procedure - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Recruiting | National Cancer Institute (NCI) | 42 | 2022-08-02 | 2026-10-14 |
| The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials Binimetinib, Encorafenib, Vemurafenib - Solid Tumors | Phase 4 | Recruiting | Pfizer | 210 | 2022-07-05 | 2026-10-19 |
| Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases Binimetinib, Encorafenib, Questionnaire Administration - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 35 | 2021-12-27 | 2026-04-16 |
| Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement Binimetinib, Conventional Surgery, Encorafenib - Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node | Phase 2 | Terminated | ECOG-ACRIN Cancer Research Group | 3 | 2021-09-22 | 2026-10-06 |
| Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma Binimetinib, Imatinib - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Recruiting | University of California, San Francisco | 25 | 2021-03-03 | 2026-08-18 |
| A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases Binimetinib, Encorafenib, Ipilimumab - Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Recruiting | SWOG Cancer Research Network | 112 | 2021-01-06 | 2026-09-15 |
| Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma Binimetinib, Nivolumab, Questionnaire Administration - Clinical Stage III Cutaneous Melanoma AJCC V8, Clinical Stage IV Cutaneous Melanoma AJCC V8 | Phase 2 | Terminated | Jonsson Comprehensive Cancer Center | 3 | 2020-12-03 | 2024-12-04 |
| Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation Binimetinib, Encorafenib - Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 6 | 2020-11-16 | 2024-05-06 |
| Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer Binimetinib, Encorafenib, Nivolumab - BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present | Phase 2 | Active not recruiting | Providence Health & Services | 24 | 2020-10-30 | 2026-04-13 |
| Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer Binimetinib, Encorafenib, Nivolumab - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma | Phase 1 | Terminated | University of California, San Francisco | 2 | 2020-08-31 | 2023-01-09 |
| Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer Binimetinib, Brigatinib - ALK Gene Rearrangement, Lung Non-Small Cell Carcinoma | Phase 1 | Terminated | University of California, San Francisco | 3 | 2020-02-25 | 2022-10-17 |
| Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer Binimetinib, Palbociclib, Trifluridine and Tipiracil Hydrochloride - Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8 | Phase 2 | Completed | Academic and Community Cancer Research United | 102 | 2019-10-29 | 2024-08-22 |
| Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer Binimetinib, Hydroxychloroquine - Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 | Phase 1 | Completed | M.D. Anderson Cancer Center | 34 | 2019-10-22 | 2026-04-06 |
| Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer Anti-OX40 Antibody PF-04518600, Avelumab, Binimetinib - Stage III Breast Cancer, Stage IIIA Breast Cancer | Phase 2 | Active not recruiting | Laura Huppert, MD, BA | 145 | 2019-07-08 | 2026-04-17 |
| A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors Avelumab, Binimetinib, Talazoparib - Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | Pfizer | 36 | 2018-08-15 | 2022-01-26 |
Showing 20 of 52. Sign in to see all of them.
Melanoma (14) · Lung Neoplasms (7) · Colorectal Neoplasms (6) · Pancreatic Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (5) · Neoplasm Metastasis (4) · Breast Neoplasms (3) · Colonic Neoplasms (3) · Hematologic Neoplasms (3) · Multiple Myeloma (3) · Ovarian Neoplasms (3) · Rectal Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Adenocarcinoma of Lung (2) · Brain Neoplasms (2)
Pfizer (11) · National Cancer Institute (NCI) (7) · Array Biopharma, now a wholly owned subsidiary of Pfizer (4) · Jonsson Comprehensive Cancer Center (3) · Memorial Sloan Kettering Cancer Center (3) · University of California, San Francisco (3) · Academic and Community Cancer Research United (2) · M.D. Anderson Cancer Center (2) · Array BioPharma (1) · Children's Hospital Los Angeles (1) · City of Hope Medical Center (1) · Dana-Farber Cancer Institute (1) · ECOG-ACRIN Cancer Research Group (1) · Fondazione Melanoma Onlus (1) · H. Lee Moffitt Cancer Center and Research Institute (1)
United States (45) · Italy (11) · Spain (10) · United Kingdom (10) · France (9) · Germany (9) · Australia (8) · Canada (8) · Netherlands (8) · Switzerland (8) · Belgium (5) · Greece (4) · Puerto Rico (4) · Brazil (3) · Czechia (3)
Ping Chi, MD, PhD (2) · Amit Oza, MD (1) · Andrew E Hendifar (1) · Antoni Ribas (1) · Ardaman Shergill (1) · Array BioPharma (1) · Bora Lim (1) · Chloe E Atreya, MD, PhD (1) · Christos Fountzilas (1) · Collin Blakely, MD, PhD (1) · Edward Garon (1) · Geoffrey I Shapiro (1) · Geoffrey Shapiro, MD, PhD (1)
PMID 23414587, PMID 26586415, PMID 28284557, PMID 29573941, PMID 30181415, PMID 30219628, PMID 31213500, PMID 31437754, PMID 32379297, PMID 32463741, PMID 32669376, PMID 33048619, PMID 34052705, PMID 34091420, PMID 34376578, PMID 35041493, PMID 35133871, PMID 35138919, PMID 35294522, PMID 35862871, PMID 36049147, PMID 36351402, PMID 36608320, PMID 36653848, PMID 37053535, PMID 37309702, PMID 37322121, PMID 37379764, PMID 37499521, PMID 37506329, PMID 37534686, PMID 37597246, PMID 37934000, PMID 38167503, PMID 38591867, PMID 39315864, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40439484, PMID 40549341, PMID 40865033, PMID 41066729, PMID 41914670, PMID 42550831
U10CA180820 (4), 2014 (2), P30CA015083 (2), U10CA180821 (2), U24CA196172 (2), 2018 (1), 2023 (1), P01CA168585 (1), U10CA180868 (1), U10CA180888 (1), UM1CA186688 (1)